Search companies

Live

Tuesday, 17 November 2026 · 580 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

Imugene Receives $2 Million R&D Refund to Support Azer-Cel Trial

Imugene Limited (IMU) · Health care

IMU: $0.035 -2.78% · MC: $20M

Imugene has received an approximately $2 million R&D tax refund for FY2026, which it says will assist patient recruitment in the BTK-inhibitor combination cohort of its Phase 1b azer-cel study.

Source announcements: 2026-11-16 09:04 to 2026-11-16 09:04 Sydney time
Story updated 2026-11-16 09:09 Sydney time
SourcesImugene Receives $2.1M R&D Tax Refund
Comments